The Right Regimen, the Right Workflow: Immunotherapy Insights for Advanced Non-Small Cell Lung Cancer in the Absence of Targetable Mutations

This activity was originally presented at the 2026 HOPA Annual Conference in New Orleans, LA.

Advanced non-small cell lung cancer (NSCLC) imposes a substantial clinical burden to patients, as nearly 40% present with metastatic disease that contributes to poor long-term survival despite therapeutic advances. These individuals require complex systemic therapy. Immunotherapy options such as immune checkpoint inhibitors (ICIs) have reshaped the first-line treatment landscape by offering the possibility of durable responses and long-term survival for a subset of patients, yet the proliferation of monotherapy, combination approaches, and dual ICI regimens has made selection and ongoing management increasingly nuanced. This program provides oncology pharmacists with an up-to-date, practical review of survival outcomes across NSCLC subgroups and histologies, examining how guidelines integrate pivotal trial data to support evidence-based first-line treatment decision-making. Through focused, case-based discussions, expert faculty will explore key concepts such as aligning regimen selection with patient comorbidities and preferences, navigating operational and workflow constraints, and applying best practices for the recognition and management of immune-related adverse events (irAEs), including those requiring rapid escalation of immunosuppression and multidisciplinary coordination. This program is intended to support oncology pharmacists' ability to interpret evolving survival data, anticipate and manage irAEs, and optimize clinic and electronic medical record workflows for individuals with advanced NSCLC.

Target audience: Oncology pharmacists

Type of activity: Application

Release date: April 15, 2026

Expiration date: April 15, 2027

Learner level: Advanced

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the clinical evidence and long-term survival data of foundational immunotherapies to inform optimal first-line treatment selection in advanced non-small cell lung cancer (NSCLC)
• Identify key clinical and operational differences among immune checkpoint inhibitor regimens in advanced NSCLC to develop streamlined, evidence-based institutional treatment pathways
• Apply evidence-based approaches to the early detection and effective management of immune-related adverse events from infusion-based immunotherapies, including prolonged and late-onset toxicities